- Home
- CBRL vs MNPR Comparison
CBRL vs MNPR Comparison
Compare CBRL & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CBRL | MNPR |
|---|---|---|
| Founded | 1969 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 640.9M | 531.6M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | CBRL | MNPR |
|---|---|---|
| Price | $27.70 | $75.22 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 13 |
| Target Price | $36.88 | ★ $97.83 |
| AVG Volume (30 Days) | ★ 2.2M | 155.1K |
| Earning Date | 12-09-2025 | 11-13-2025 |
| Dividend Yield | ★ 3.54% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.75 | N/A |
| Revenue | ★ $3,435,783,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.95 | N/A |
| P/E Ratio | $37.63 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $25.25 | $21.00 |
| 52 Week High | $71.93 | $105.00 |
Technical Indicators
Market Signals| Indicator | CBRL | MNPR |
|---|---|---|
| Relative Strength Index (RSI) | 39.41 | 43.12 |
| Support Level | $25.25 | $74.51 |
| Resistance Level | $30.20 | $79.31 |
| Average True Range (ATR) | 1.46 | 6.38 |
| MACD | 0.42 | -0.87 |
| Stochastic Oscillator | 48.69 | 9.23 |
Price Performance
Historical ComparisonAbout CBRL Cracker Barrel Old Country Store Inc
Cracker Barrel Old Country Store Inc operates hundreds of full-service restaurants throughout the United States. The Cracker Barrel stores consists of a restaurant with a gift shop. The restaurants serve breakfast, lunch and dinner. The gift shop offers a variety of decorative and functional items specializing in rocking chairs, holiday gifts, toys, apparel and foods.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.